• A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 52-Week Treatment Period as an Early Intervention in Patients with Attenuated Psychosis Syndrome OPEN ENROLLMENT
• ALK3831-A307: A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness OPEN ENROLLMENT
• Protocol: ALK3831-A308 A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder OPEN ENROLLMENT